ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 696

Risk Factors for EARLY Mortality in Scleroderma Patients: A Report From the EULAR Scleroderma Trials and Research Group (EUSTAR) Database

Patricia E. Carreira1, Loreto Carmona2, Beatriz E. Joven3, Christopher P. Denton4, Yannick Allanore5, Ulrich A. Walker6, Marco Matucci-Cerinic7, Ulf Müller-Ladner8 and Eustar9, 1Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 2Health Sciences School, Universidad Camilo José Cela, Villanueva de la Cañada, Spain, 3Rheumatology, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, Madrid, Spain, 4Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, 5Rheumatology, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 6Rheumatology, Universitäts-Poliklinik, Felix-Platter Spital, Basel, Switzerland, 7Department of Biomedicine & Division of Rheumatology AOUC, University of Florence, Florence, Italy, 8Abt. f. Rheumatologie u. klinische Immunologie, Osteologie, Physikalische Therapie, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany, 9Florence

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: morbidity and mortality, risk assessment and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects and Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose: to identify risk factors for early mortality in a large group of recently diagnosed systemic sclerosis (SSc) patients

Methods: EUSTAR collects prospectively the Minimal Essential Data Set (MEDS), on all sequential patients fulfilling the American College of Rheumatology diagnostic criteria in participating centres, in an annual basis. Patients with disease duration of less than 3 years at the first EUSTAR entry, and with at least one follow-up visit, were selected. Baseline data from the first visit were compared between SSc cases registered as dead up to December 2011, and living patients. Kaplan-Meier analysis was used to estimate survival, and Cox proportional hazards regression analysis, corrected by age at the end of follow-up, was used to identify factors associated with early mortality.

Results: From 1188 patients, 671 (19% men) had at least one follow-up visit. From those, 276 had diffuse and 348 had limited disease. Mean age at entry was 53±15 years, and at first non Raynaud symptom 50±15 years. Mean disease duration was 19±6 months and time between the onset of Raynaud and first non Raynaud symptom was 4±7 months. After 43±24 months of follow-up from the first visit and 57±26 months from the first non Raynaud symptom, 111 patients (17%) were dead. Death occurred after 43±27 months from the first non Raynaud symptom. Mean survival for the whole group was 116 (95%CI 110-122) months. By Cox proportional hazards regression multivariate analysis, main risk factors for mortality were: higher skin score (HR 1-03, 95%CI 1.003-1.05, p=0.02), acute phase reactants elevation (HR 1.8, 95%CI 1.1-2.8; p=0.02), joint contractures (HR 1.8; 95%CI 1.1-2.8; p=0.002), CK elevation (HR 1.9, 95%CI 1.1-3.3, p=0.02), cardiac blocks (HR 2.1, 95%CI 1.3-3.3, p=0.004), diastolic dysfunction (HR 2.1, 95%CI 1.3-3.3, p=0.002) and ischemic ulcers (HR 1.9, 95%CI 1.2-2.9, p=0.007). When only diffuse patients were analyzed, CK elevation, FVC below 80% and pulmonary hypertension were the risk factors for mortality. In the other hand, bad prognostic factors in limited patients were joint contractures, CK elevation, cardiac blocks, proteinuria and renal crisis.

Conclusion: In this large group of SSc patients, risk factors for early mortality are higher skin involvement with more severe vascular disease and cardiac involvement, especially if associated to elevated acute phase response. Muscular and cardiac involvement appear as a risk factor for mortality both in limited and diffuse disease, whereas lung and renal involvement have a mayor impact in diffuse and limited cases respectively.


Disclosure:

P. E. Carreira,
None;

L. Carmona,
None;

B. E. Joven,
None;

C. P. Denton,
None;

Y. Allanore,
None;

U. A. Walker,
None;

M. Matucci-Cerinic,
None;

U. Müller-Ladner,
None;

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-factors-for-early-mortality-in-scleroderma-patients-a-report-from-the-eular-scleroderma-trials-and-research-group-eustar-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology